Loading…
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-41M | $-38M | $-24M | -39.0% | - | 74.3% |
| 2024 | $0M | $-22M | $-22M | $-20M | -46.0% | -100.0% | 11.2% |
| 2023 | $0M | $-19M | $-20M | $-18M | -9684.2% | 2.7% | 7.4% |
| 2022 | $0M | $-18M | $-18M | $-16M | -631.8% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0.07 | 0.08 | 0 | 0 |
| Operating Revenue | - | 0.07 | 0.08 | 0 | 0 |
| Cost Of Revenue | 0.12 | 0.01 | 0 | - | - |
| Gross Profit | -0.06 | 0.06 | 0.08 | - | - |
| Operating Expense | - | 17.92 | 19.16 | 22.49 | 41.76 |
| Research And Development | - | 11.27 | 12.77 | 15.61 | 18.33 |
| Selling General And Administration | - | 6.65 | 6.38 | 6.99 | 23.43 |
| Total Expenses | - | 17.93 | 19.16 | 22.49 | 41.76 |
| Operating Income | - | -17.85 | -19.08 | -22.49 | -41.76 |
| Total Operating Income As Reported | - | -17.85 | -19.08 | -22.49 | -41.76 |
| EBITDA | - | -17.78 | -18.70 | -22.15 | -41.37 |
| Normalized EBITDA | - | -17.54 | -18.28 | -22.19 | -41.30 |
| EBIT | - | -18.18 | -19.08 | -22.49 | -41.76 |
| Interest Income | -0.01 | - | - | - | - |
| Interest Expense | 0.01 | 0.03 | 0.03 | - | - |
| Net Interest Income | - | -0.03 | -0.03 | 0.90 | 3.29 |
| Other Non Operating Income Expenses | - | -0.08 | -0.03 | -0.20 | 0.63 |
| Other Income Expense | - | -0.32 | -0.45 | -0.16 | 0.56 |
| Interest Income Non Operating | -0.01 | - | - | - | - |
| Interest Expense Non Operating | 0.01 | 0.03 | 0.03 | - | - |
| Net Non Operating Interest Income Expense | - | -0.03 | -0.03 | 0.90 | 3.29 |
| Pretax Income | - | -18.21 | -19.56 | -21.75 | -37.92 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income From Continuing And Discontinued Operation | - | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income From Continuing Operation Net Minority Interest | - | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income | - | -18.21 | -19.56 | -21.75 | -37.92 |
| Net Income Common Stockholders | - | -18.21 | -19.56 | -22.37 | -37.92 |
| Net Income Including Noncontrolling Interests | - | -18.21 | -19.56 | -21.75 | -37.92 |
| Normalized Income | - | -17.96 | -19.14 | -21.79 | -37.85 |
| Diluted NI Availto Com Stockholders | - | -18.21 | -19.56 | -22.37 | -37.92 |
| Basic Average Shares | - | 0.48 | 1.39 | 18.36 | 36.21 |
| Diluted Average Shares | - | 0.48 | 1.39 | 18.36 | 36.21 |
| Reconciled Depreciation | - | 0.39 | 0.38 | 0.34 | 0.40 |
| Reconciled Cost Of Revenue | 0.12 | 0.01 | 0 | - | - |
| Total Unusual Items | - | -0.24 | -0.42 | 0.04 | -0.07 |
| Total Unusual Items Excluding Goodwill | - | -0.24 | -0.42 | 0.04 | -0.07 |
| Special Income Charges | - | - | - | 0 | 0.76 |
| Other Special Charges | - | - | - | - | -0.76 |
| Gain On Sale Of Security | - | -0.24 | -0.42 | 0.04 | -0.07 |
| General And Administrative Expense | - | 6.65 | 6.38 | 6.99 | 23.43 |
| Other Gand A | - | 6.65 | 6.38 | 6.99 | 23.43 |
| Salaries And Wages | - | 0.61 | 0.29 | - | - |
| Total Other Finance Cost | 0.01 | - | 0.03 | -0.90 | -3.29 |
| Other Operating Expenses | 0.12 | 0.01 | - | -0.11 | - |
| Otherunder Preferred Stock Dividend | - | - | 0 | 0.62 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Benitec Biopharma Inc.this co. | BNTC | $380M | -10.01 | 3.90 | -39.0% | -6.83 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 |
| - |
| - |
| - |
| - |
| - |
| 28.41 |
| -190.9% |
| -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Peer Median | - | -3.75 | 1.87 | -37.2% | -3.41 | |